ASP Isotopes (NASDAQ:ASPI) Given “Buy” Rating at Canaccord Genuity Group

ASP Isotopes (NASDAQ:ASPI)‘s stock had its “buy” rating restated by analysts at Canaccord Genuity Group in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $11.00 price target on the stock. Canaccord Genuity Group’s price target indicates a potential upside of 127.04% from the company’s current price.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Price Performance

ASPI stock traded down $0.22 during trading on Tuesday, reaching $4.85. 2,145,449 shares of the company were exchanged, compared to its average volume of 5,222,808. The company has a 50-day moving average of $5.10 and a two-hundred day moving average of $6.83. The company has a market capitalization of $537.02 million, a price-to-earnings ratio of -2.26 and a beta of 3.59. ASP Isotopes has a twelve month low of $3.92 and a twelve month high of $14.49. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings data on Friday, April 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.70). The company had revenue of $33.32 million for the quarter, compared to analyst estimates of $2.03 million. ASP Isotopes had a negative return on equity of 307.82% and a negative net margin of 734.14%. As a group, equities analysts predict that ASP Isotopes will post -0.24 earnings per share for the current fiscal year.

Insider Transactions at ASP Isotopes

In other news, COO Robert Ainscow sold 25,000 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $4.51, for a total value of $112,750.00. Following the sale, the chief operating officer directly owned 1,512,817 shares of the company’s stock, valued at approximately $6,822,804.67. This represents a 1.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 14.40% of the company’s stock.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently modified their holdings of ASPI. Quantbot Technologies LP bought a new stake in shares of ASP Isotopes in the 3rd quarter valued at $34,000. BNP Paribas Financial Markets boosted its stake in shares of ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after purchasing an additional 2,548 shares during the last quarter. IFP Advisors Inc bought a new stake in shares of ASP Isotopes in the 4th quarter valued at $48,000. Pictet Asset Management Holding SA bought a new stake in shares of ASP Isotopes in the 4th quarter valued at $61,000. Finally, Close Asset Management Ltd bought a new stake in shares of ASP Isotopes in the 3rd quarter valued at $72,000. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.